Smith & Nephew BIRMINGHAM HIP (trademark Smith & Nephew) Resurfacing (FDA Approved)
Design of the hip resurfacing started in 1989 and the first implantation was performed in February of 1991. Since 1991 500,000 have been fitted in Europe, the UK, and Australia. 10 May, 2006 US Food and Drug Administration (FDA) approved the BIRMINGHAM HIP (trademark Smith & Nephew)
Hip Resurfacing conserves more of a patient’s bone than a traditional hip replacement, enabling younger, more active patients to undergo hip replacement surgery while preserving all future surgery options, including a primary hip replacement. Hip Resurfacing also offers patients an increased better range of motion with a greatly reduced risk of dislocation. In our experience we have never heard of a hip resurfacing dislocating.
Features of the BHR include:
- Less bone resection than conventional total Hip Arthroplasty
- Availability of global, long-term clinical outcomes data
- Functionally optimized metallurgy and design
This successful, bone conserving hip resurfacing system is well documented through independent clinical and laboratory studies. Additional clinical evidence supporting the BHR is published by national and regional arthroplasty registries. This bone conserving procedure, combined with an implant design intended to decrease the risk of dislocation and excellent survivorship, makes the BHR ideal for the younger, active male patient.
AVN and Osteoarthritis sufferers
Some organisations claim that hip resurfacing is an alternative to total hip replacement for patients suffering from abnormalities of the hip, including osteoarthritis. However sufferers with bone disease such as AVN and osteoarthritis should be cautious. Careful assessment of such candidates must take place before deciding whether hip resurfacing would be suitable.